CDc25 phosphatase

(redirected from CDC25)
Also found in: Wikipedia.

CDc25 phosphatase

A group of intracellular enzymes that regulate cell division, some of which may contribute to the conversion of normal cells to cancer cells.
See also: phosphatase
References in periodicals archive ?
Subsequent work revealed that let-7 regulates a number of other oncogenes, including CCND2 (cyclin D2), CDK6 (cyclin-dependent kinase 6), CDC25 [cell division cycle 25 homolog C (S.
4] Genes: let-7; HRAS, v-Ha-ras Harvey rat sarcoma viral oncogene homolog; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; NRAS, neuroblastoma RAS viral (v-ras) oncogene homolog; CCND2, cyclin D2; CDK6, cyclin-dependent kinase 6; CDC25, cell division cycle 25 homolog C (S.
Up regulation of the CDC25 Aphosphatase down-stream of the NPM/ ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.
Specific activation of CDC25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins.
Elimination of cdc2 phosphorylation sites in the CDC25 phosphatase blocks initiation of M-phase.
Functions and regulation mechanisms of CDC25 in cell cycle progression and response to cell cycle checkpoint.
PARIS and LAUSANNE, Switzerland, September 7 /PRNewswire/ -- Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
CDC25 is a key enzyme involved in the regulation of cell cycle.
Jean-Luc Belingard, Ipsen's Chairman and Chief Executive Officer said: "We are delighted that Ipsen's CDC25 inhibitor will be progressed toward clinical development by Debiopharm, a company with a strong track record in oncology.
In oncology, BN-83495 has moved into phase II, Decapeptyl([R]) 6 month was given a collective green light in Europe, and we have successfully optimised our pipeline, notably with the licensing out of CDC25 to Debiopham and the redesign of the Group's collaboration with Spirogen for SJG-136, a DNA minor groove binding agent.
On September 7, 2009 - The Group and the Debiopharm Group (Debiopharm), announced the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
The more highly homologous C-terminal regions (~60% pair-wise identity over ~200 amino acids) contain the catalytic functionality of the Cdc25s (Rudolph, 2007).